Thoracic Neoplasms  >>  lifastuzumab vedotin (DNIB0600A)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lifastuzumab vedotin (DNIB0600A) / Roche
NCT01363947: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

Completed
1
87
US, Europe
DNIB0600A
Genentech, Inc.
Non-Small Cell Lung Cancer, Ovarian Cancer
06/16
06/16

Download Options